Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.55 |
| ▸ | CNR1 | P21554 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10112974 | 0.82 | CNR2 (0.55) | CNR2LMNANPSR1EPHX2TRPV1 | |
| SCHEMBL10115581 | 0.77 | CNR2 (0.56) | CNR2CNR1LMNANPSR1CA12 | |
| SCHEMBL10115869 | 0.75 | CNR2 (0.54) | CNR2CNR1LMNANPSR1CA12 | |
| SCHEMBL15085797 | 0.75 | CNR2 (0.71) | CNR2CNR1NPSR1KMT2A | |
| SCHEMBL2984848 | 0.73 | ALDH1A1 (0.37) | LMNANPSR1EPHX2KMT2A | |
| SCHEMBL6764498 | 0.72 | CNR2 (0.59) | CNR2CNR1CA12CA1CA2 | |
| SCHEMBL30965820 | 0.72 | POLB (0.63) | CNR2CNR1CA12CA1CA2 | |
| SCHEMBL10253368 | 0.71 | CNR2 (1.00) | CNR2CNR1LMNANPSR1CA12 | |
| SCHEMBL1147258 | 0.70 | TRPV1 (0.56) | CNR2CNR1CA12CA1CA2 | |
| SCHEMBL9466294 | 0.70 | MAPT (0.60) | CNR2CNR1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| EP-2014285-B1 | NPYY5 antagonists | SHIONOGI & CO (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-1249233-B9 | NPYY5 ANTAGONISTS | SHIONOGI & CO (JP) | 2009-08-05 | — | — | EP | disclosed |
| EP-2014285-A1 | NPYY5 antagonists | Shionogi&Co., Ltd. (JP) | 2009-01-14 | — | — | EP | disclosed |
| EP-1249233-B1 | NPYY5 ANTAGONISTS | SHIONOGI & CO (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20040180964-A1 | NPY Y5 antagonist | SHIONOGI & CO. | 2004-09-16 | — | — | US | disclosed |
| US-20040176462-A1 | NPY Y5 antagonist | SHIONOGI & CO., LTD. | 2004-09-09 | — | — | US | disclosed |
| US-6699891-B1 | SULFONAMIDE OR SULFINAMIDE DERIVATIVES; NEUROPEPTIDE Y ANTAGONISTS; ANOREXIGENIC OR ANTIOBESITY AGENTS | SHIONOGI & CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-1249233-A1 | NPYY5 ANTAGONISTS | SHIONOGI & CO., LTD. (JP) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176462-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | CNR2 31/4885CNR1 13/4885LMNA 2375/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | CNR2 30/4885CNR1 15/4885LMNA 2068/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | CNR2 29/4885CNR1 13/4885LMNA 1857/4885 |
| US-20040180964-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | CNR2 31/4885CNR1 13/4885LMNA 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.